Sjögren's disease & overlap diseases
Targeted proteomics identifies differentially expressed proteins in Sjögren’s disease with incident lymphoma
Authors' conclusion
We identified altered protein expression and an increased IFN system activation in SjD with incident lymphoma and pre-lymphoma.
Study context
- Population
- Patients with primary Sjögren's disease (SjD) with and without lymphoma, and healthy blood donors
- Participants
- 18 / 4 / 21 / 6 / 39
- Comparison
- SjD with incident lymphoma vs SjD without lymphoma, SjD with historical lymphoma and healthy blood donors
- SjD with incident lymphoman = 18
- SjD pre-lymphoman = 4
- SjD without lymphoman = 21reference
- SjD with historical lymphoman = 6reference
- Healthy blood donorsn = 39reference
- Outcome
- Serum protein biomarkers (differentially expressed proteins) for lymphoma development
Methodological detailstargeted proteomics (Olink Target 96 Immuno-Oncology panel), false discovery rate (FDR)-adjusted p value of 0.05, longitudinal sampling (before treatment and at 6, 12 and 24 months)
- Targeted proteomics (Olink Target 96 Immuno-Oncology panel)
- FDR-adjusted p value of 0.05
- Longitudinal sampling (before treatment and at 6, 12 and 24 months)
Main finding
As reported in the abstract
Differentially expressed proteins
- Differentially expressed proteins in SjD with incident lymphoma vs both SjD without lymphoma and healthy controls
- 18
Observational data: associations, not effects.
Further findings
CD40 expression, SjD pre-lymphoma
- Upregulated CD40 in SjD pre-lymphoma vs SjD without lymphoma and healthy controls
pIFN scores
- All SjD groups elevated pIFN scores vs healthy controls; SjD pre-lymphoma showed the most distinct IFN activation
Original publication
Targeted proteomics identifies differentially expressed proteins in Sjögren’s disease with incident lymphoma. RMD Open. Published 23 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →